Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ALK I1171N ALK pos |
Therapy | Lorlatinib |
Indication/Tumor Type | diffuse large B-cell lymphoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK I1171N ALK pos | diffuse large B-cell lymphoma | predicted - sensitive | Lorlatinib | Case Reports/Case Series | Actionable | In a clinical case study, Lorbrena (lorlatinib) treatment resulted in an ongoing complete metabolic response 20 months post-transplant in a patient with an ALK-positive large B-cell lymphoma harboring ALK I1171N (PMID: 36809056). | 36809056 |
PubMed Id | Reference Title | Details |
---|---|---|
(36809056) | Lorlatinib Induces Rapid and Durable Response in Refractory Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma. | Full reference... |